Tuesday, 6 December 2016

Clonal hematopoiesis may help predict cancer patients at risk for fatal form of leukemia

Clonal hematopoiesis may help predict cancer patients at risk for fatal form of leukemia: Patients successfully treated for breast, colon and other cancers can go on to develop an often-fatal form of leukemia, sometimes years after completion of treatment, due to a genetic mutation leading to secondary malignancies known as therapy-related myeloid neoplasms (t-MNs).
Published on December 4, 2016 at 11:12 PM · No Comments
Patients successfully treated for breast, colon and other cancers can go on to develop an often-fatal form of leukemia, sometimes years after completion of treatment, due to a genetic mutation leading to secondary malignancies known as therapy-related myeloid neoplasms (t-MNs).
A study conducted by researchers at The University of Texas MD Anderson Cancer Center revealed pre-leukemic mutations, called clonal hematopoiesis, may predict whether patients develop t-MNs. Clonal hematopoiesis appears to function as a biomarker for patients who develop t-MNs, a leukemia recognized for its extremely poor prognosis. The study findings were published today in The Lancet Oncology and presented at the annual meeting of the American Society of Hematology in San Diego.
"Therapy-related myeloid neoplasms occur in about 5 percent of cancer patients who were treated with chemotherapy and/or radiation therapy," said Andy Futreal, Ph.D., chair ad interim of Genomic Medicine. "In most cases, it is fatal, and currently there is no way to predict who is at risk or prevent it.
Being able to detect t-MNs earlier is crucial given that the disease usually occurs three to eight years following chemotherapy and/or radiation therapy.
"T-MNs are a problem that needs urgent attention," said Koichi Takashi, M.D., assistant professor of Leukemia and Genomic Medicine and a co-author on the Lancet Oncology paper. "Since many cancer patients are now living longer, t-MNs are an increasing concern for many cancer survivors."
Futreal's team studied 14 patients with t-MNs and found traces of pre-leukemic mutations or clonal hematopoiesis in 10. To determine if pre-leukemic mutations could reliably predict whether the patients would develop leukemia, the researchers compared prevalence of pre-leukemic mutations in the 14 patients with 54 patients who did not develop t-MNs after therapy.
"We found that prevalence of pre-leukemic mutations was significantly higher in patients who developed t-MNs (71 percent) versus those who did not (26 percent)," said Futreal. "We also validated these findings in a separate cohort of patients. Based on these findings, we believe pre-leukemic mutations may function as a new biomarker that would predict t-MNs development."
In the sample of 14 patients with t-MNs, the team looked at samples of bone marrow at the time of t-MNs development and blood samples obtained at the time of their primary cancer diagnosis.
"We found genetic mutations that are present in t-MNs leukemia samples actually could be found in blood samples obtained at the time of their original cancer diagnosis," said Takahashi. "Based on this finding, we believe the data suggest potential approaches of screening for clonal hematopoiesis in cancer patients that may identify patients at risk of developing t-MNs, although further studies are needed."
University of Texas M. D. Anderson Cancer Center

Monday, 5 December 2016


LOS ANGELESOct. 23, 2016 /PRNewswire/ -- International Open Access Week - a global event in conjunction with this year's Open Access Week Advisory Committee, entering in its 9th international year. The event is going to be celebrated from October 24 to 30, 2016.The announced theme for this year is "Open in Action."
International Open Access Week is an opportunity for the academic and research community to learn about the potential benefits of Open Access and to share the information with their colleagues. Therefore, "Open Access Week" celebration will help to inspire huge participation in order to make Open Access a new norm in the research and scholarship.
"Open Access" has the power to transform the research and scientific information dissemination with the free, immediate, online access of the results along with the right to use and re-use the published results as needed. Numerous Research funding agencies, academic institutions, researchers and scientists, teachers, students, and general public are supporting the movement of Open Access which is gaining additional momentum every year.
This Open Access Week provides an opportunity for every members of the community to take action in keeping this momentum moving forward. So Get Enrolled. Taking part in Open Access Week can be a simple way to become a part of the future societal benefits.
OMICS International has been a follower of Open Access system since its inception. The lead taken by OMICS International in this regard has been a great success and we would like to ensure the continuation of the same.
With the following present Open Access week theme of "Open in Action" we request our distinguished Editors, Authors and reviewers to participate in this campaign and share their knowledge and experience with us. We request all the associated eminent personalities send us their suggestions, comments at https://www.omicsonline.org/contact.php
About OMICS International
OMICS Group with its 2000+ employees has been supported by 50000+ well-qualified scientists as editorial board members who serve on voluntary basis to disseminate healthcare and scientific information open access, and year on year this support is increasing progressively with which OMICS Group is able to grow from 10 peer reviewed journals in 2009 to 700 peer reviewed journals by 2016, and readers base increased to 30 million.
SOURCE OMICS International

Tuesday, 22 November 2016

Avoiding Endocrine Disruptors Drops Diabetes Risk: Study

Based on epidemiological data, researchers estimate that reducing exposures to certain environmental chemicals could drop people’s chances of developing the disease.
By  | October 27, 2016
Some environmental chemicals, such as plastics additives and certain pesticides, act as endocrine disruptors and can perturb animals’ metabolisms in the lab. Epidemiological studies have also linked human exposures to these substances with an increased risk for developing diabetes. A study published today (October 27) in the Journal of Epidemiology & Community Health estimates that cutting exposures by 25 percent could reduce the prevalence of diabetes by 13 percent among the elderly in Sweden.
“Extrapolating to Europe, 152,481 cases of diabetes in Europe and €4.51 billion/year in associated costs could be prevented,” the authors, led by Leonardo Trasande at New York University School of Medicine, wrote in their report.
Trasande and his colleagues used data from a study of about 1,000 elderly Swedes whose blood was sampled to estimate their exposures to certain chemicals. Specifically, the researchers looked at four so-called “diabetogens”: two phthalates (plastics additives), a polychlorinated biphenyl (PCB), and PFNA, a surface-coating compound.
From the data they calculated a reduction in diabetes risk if exposure to each compound dropped by 25 percent. Although their estimates found reducing exposure to any one chemical didn’t make a difference, cutting back on all four together resulted in a 13 percent drop in diabetes prevalence. In comparison, reducing the body mass index of the population led to an estimated 40 percent reduction in diabetes prevalence.
In a study published earlier this month in The Lancet, Trasande and his collaborators estimated that the cost associated with Americans’ exposure to endocrine-disrupting chemicals—in healthcare expenses, intellectual disabilities, and lost days of work—is about $340 billion per year.
“Our research adds to the growing evidence on the tremendous economic as well as human health costs of endocrine-disrupting chemicals,” Trasande said in a press release.
One limitation of the paper published in The Lancet, according to Joseph Perrone, the chief science officer for the Center for Accountability in Science, is that the study “doesn't distinguish between endocrine action and endocrine disruption,” he told CNN. “This is an important distinction because activity does not by itself cause harm.”

Monday, 21 November 2016

ESCMID experts raise awareness for optimal use of antibiotics to combat AMR

Published on November 21, 2016 at 4:42 AM ·
On 18 November ESCMID is organizing a number of activities to promote prudent use of antibiotics in Europe. These include events at healthcare institutions and public campaigns on antimicrobial resistance (AMR), surveillance and antibiotic stewardship programmes in Moldova, Turkey, Spain, Cyprus and the Netherlands.
Prof. Jesús Rodríguez-Baño, ESCMID President-elect and Secretary General:
Antimicrobial resistance is a global threat that has been at the core of ESCMID’s activities – at our study groups, committees, courses and conferences over the past years. Our experts have been committed to developing hands-on solutions by supporting and promoting research and training to tackle the problem around the world. The society offers professional training and programmes on antimicrobial stewardship, infection control and surveillance resistance. It develops medical guidelines, policies for antimicrobial use, and initiatives to promote novel diagnostics, vaccines and therapies.
The society has undertaken a number of initiatives to effectively fight the growing problem. Only in September ESCMID together with the American Society for Microbiology organized an international conference on drug development to meet the AMR challenge. Drawing from the outcomes of the conference ESCMID plans to publish a position paper on its strategy and role in the fight against AMR.
AMR will once again be one of the main topics at ECCMID, the world’s largest congress in infectious diseases and clinical microbiology usually gathering some 12,000 specialists, from 22 – 25 April 2017 in Vienna. A book on antimicrobial stewardship produced by ESCMID and ESCMID Study Group for Antibiotic Policies (ESGAP) is due for publication in April 2017. The book has been developed by key experts in the field as a practical ‘hands-on’ book to help antimicrobial stewardship team members design and implement their programme, in all healthcare settings. It can also be used as an undergraduate and postgraduate training tool for infectious diseases specialists, microbiologists, pharmacists, nurses, and any other professionals involved in antimicrobial stewardship.
ESCMID has been supporting governments and international organizations to develop and implement policies on evidence-based prevention, infection control, surveillance of resistance, antimicrobial stewardship and sanitation to guarantee an optimal use of antimicrobial medicines. The society welcomes the fact that the topic moved to the top of the global agenda in September when the United Nations General Assembly called a high-level meeting to address a problem that is projected to cause up to 10 million annual deaths by 2050.
Concrete efforts of ESCMID over the past years include the European Committee on Antimicrobial Susceptibility Testing (EUCAST), jointly organized by ESCMID and the ECDC, which defines so-called breakpoints required to define optimal dosing of antibiotics and thus distinguish between therapeutic success and failure. Recently EUCAST completed a review of breakpoints or fluoroquinolone and carbapenem, two of the most important groups of antibiotics, and defined breakpoints and susceptibility methods for new agents and additional bacterial species. Its experts also conducted a study that showed that phenotypic antimicrobial susceptibility testing (PAST) is a better predictor of susceptibility, while whole genome sequencing (WGS) is more useful for characterizing resistance genes and mechanisms.
One of the more recent initiatives include European Committee on Infection Control (EUCIC), which was created in 2014 to support the implementation of infection control and preventive (ICPM) measures to reduce the burden of healthcare-associated infections. Among many on going projects, EUCIC is currently involved in the PERCEPT-R project, which aims to investigate the perceptions of infection control specialists regarding AMR and infection prevention and control in different countries, and the role played by the cultural, contextual and behavioural aspect on the prevention of AMR. In order to contribute to the harmonisation of ICPM and standardisation of procedures, EUCIC is working on developing new educational tools that could provide a new generation of infection control specialists with a global European perspective and competence. Increasing burden of infectious diseases, epidemiology as well as demographic changes and mass migration are overwhelming facts that no nation alone will be able to overcome.
EUCIC together with major stakeholders and the national representatives in the EUCIC advisory board is currently developing a European training programme for infection control in healthcare settings.
AMR will continue to be a focus for ESCMID education
ESCMID has offered courses relevant to antimicrobial stewardship and drug-resistant infections this year, including:
  • 18-19 January (Cape Town, South Africa): Diagnosis and management of drug-resistant TB.
  • 7-8 April (Ijmuiden Aan Zee, Netherlands): Antimicrobial stewardship.
  • 29 May - 1 June 2016 (Groningen, Netherlands): Infection Prevention and Control: Let's Get Practical!, ESCMID Postgraduate Technical Workshop.
  • 20-23 September (Bochum, Germany): Antimicrobial susceptibility testing and surveillance from laboratory to clinic.
Further courses are planned for the coming 12 months, including:
  • Hospital-Acquired Infections: Understanding the Magnitude and Needed Interventions, 23 – 24 March in Muscat, Oman
  • Antimicrobial Resistance Across Europe and the Far East: Issues and Solutions, 26 -27 May 2017, Taipei, Taiwan
  • Advanced Technical Workshop: Infection and Resistance Prevention in the Regional Healthcare Network, 31 May – 1 June 2017, Groningen, Netherlands
  • Emerging Antibiotic Resistance in Gram-Negative Bacteria: Problems and Solutions, 14 - 15 September 2017, Fribourg, Switzerland
  • Antimicrobial Stewardship: Principles and Practice, 4 - 6 October 2017, Istanbul, Turkey

Monday, 14 November 2016

Meet With World Leading Epidemiologist

Epidemiologic researchers, educators, and policy makers from academia, public health, government, and industry are invited to come together at the Sixth Epidemiology Congress of the France. The Congress aims to showcase and promote the diversity of study, practice and policy within epidemiology as a whole to improve the health of diverse populations. The meeting will include plenary addresses from visionary leaders; symposia addressing emerging issues cutting across topical fields; spotlight and poster sessions selected from submitted abstracts; and awards for a variety of accomplishments in our field.For more details visit http://epidemiology.conferenceseries.com/ 

Marseille Conferences

Marseille  Conferences

Marseille, also known as Marseilles in English, is a major city in France. The capital of the Bouches-du-Rhône department and Provence-Alpes-Côte d'Azur region, Marseille. Known to the ancient Greeks and Romans as Massalia. Marseille was the most important trading centre in the region and the main commercial port of the French Empire. Marseille is now France's largest city on the Mediterranean coast and the largest port for commerce, freight and cruise ships. The city was European Capital of Culture, together with Košice, Slovakia, in 2013. It hosted the European Football Championship in 2016, and will be the European Capital of Sport in 2017. The city is home to several campuses of Aix-Marseille University and part of one of the largest metropolitan conurbations in France, the Metropolis of Aix-Marseille-Provence.

Market Analysis & Funding  for Pharma | Nursing | Immunology |Neuroscience | Cancer | Engineering | CardiologyDiabetes  in Marseille


Examination depends on the geological development rate from exploration and headway appeared amid the specific year as far as billion dollars at Marseille. The report highlights that the development of pharmaceutical business sector has been expanded from 2006 to 2008 then it backs off in the year of 2012 and again there was a consistent development appeared during the time from 2014 to 2015. This figure had expanded to 28.2% by2016 and anticipated that would continue as before.
Figure 1: Expected Growth Rate of Pharma Sector at Marseille (in Billion Dollars)


As indicated by business sector investigation report, Immigration of outside(- prepared) attendants can make a huge commitment to a nation's medical caretaker workforce. Remote medical caretakers made up 40.8%, 52% and 69.23% of the attendant workforce in the year 2000 to 2010. The extent of outside prepared enrolled medical attendants in france in the year 2015 was observed to be up to 72% separately. Information demonstrate a diminished rate in the year 2005 albeit late inquires about and propels in the field of nursing are liable to be expanded in future years.
Figure 3: Year wise Gross expenditures for Nursing at Marseille (in Billion Dollars)


As the business sector report of Immunology in France shows that there is persistent decrease rate was seen in the year 2012 to 2014, that is the reason France has expanded its R&D ventures by 15% to 20% every year for most recent 2 years; while in the meantime, U.S. Research and development spending expanded at not as much as a large portion of those rates. Thus, France's venture is currently around 61% that of the U.S., and keeping on shutting. France's working class would anticipated that would extend from 35% to 75%.
Figure 4Year wise Gross expenditures on R&D in the field of Immunology


Worldwide neuroscience market size was esteemed at USD 32.09 billion in 2013 and is required to develop at a CAGR of 3.9% over the figure time frame. Key development considering qualities connected with the neuroscience market incorporate rising R&D in neuroinformatics for the improvement of effective instruments and calculations to upgrade cerebrum basically and practical mapping.
The nearness of significant government financing empowering the continuation of such research is required to keep the development stable over the gauge time frame. It is normal that novel item improvement resultant of progressing R&D will advance impact development amid the estimate time frame.
Figure 5France Neuroscience market by technology 2012-2020(USD Million)
As indicated by business sector investigation report, Cancer establishments the nation over are depending more intensely than any other time in recent memory on pharmaceutical industry financing for examination and advances. As the graphical representation proposes that there is an unconstrained development was watched structure recent years and fundings for tumor exploration was likewise observed to be comparvetively expanded for malignancy other than different zones.
Figure 6The numbers of applications received and grants awarded in recent years 2006-2016


Market Report of Marseille mirrors the unconstrained development rate in the field of electrical Engineering and Mechanical designing by 80-94.8% consistently. However the development rate was observed to be least in the field of Aeronautical Engineering and Architecture Degrees.
Figure 2: Expected Growth Rate of Engineering at Marseille (in Billion Dollars)


Worldwide cardiology business sector is developing quickly and is relied upon to reach $98.9 billion by 2020. Cardiovascular signs, for example, heart disappointment, Acute Coronary Syndrome, Atherosclerosis, Hypercholesterolemia, and Hypertension got all out endeavor subsidizing of $2.4 Billion throughout the most recent 10 years, and represented 6% of aggregate funding raised.

Figure 7Total Venture Funding’s in (billion dollar)


Around 30-40% of Endocrine endeavor is in Type 2 Diabetes. The total aggregate of novel drug Endocrine theory is practically 10x that for Type I Diabetes-focused associations in both five-year windows. Instance of non-novel: Peaks in 2011 and 2012 are financings for movement progressions of avowed drugs with a $150 million C round and a $163 million Series D. This record for 75% and 85% of those two years of Type II Diabetes financing.
Figure 8Total Venture Funding’s for Type-2 Diabetes in (billion dollar)

Marseille City Highlights

Marseille city of France has one university named Aix-Marseille University and three education institutions that are outside the university framework within the city. There are total 85 universities in France including 16 full range Universities and remaining 69 are specialized in the particular departments ranging from medical, arts, law, Sciences etc.

Universities In Marseille | Marseille Conferences

Aix-Marseille University
Université de Montpellier 1
Université de Montpellier 2
Université Paul Valery Montpellier 3
Université de Strasbourg
Université de Haute Alsace
Université de Bordeaux 
Université de Bordeaux 1
Université Michel Montaigne
Université Montesquieu
Université Ségalen
Université de Pau et du Pays de l'Adour
Université Blaise Pascal
Université d'Auvergne
Université de Rennes 1
Université de Haute Bretagne
Université de Bretagne occidentale
Université de Bretagne sud
Universite de Bourgogne
Université d'Orléans
Université Rabelais
Université de Reims
Université Paoli
Université de Franche Comté
Université de Paris 1 Panthéon Sorbonne
Université de Paris 2 PanthéonAssas
Université de Paris III Sorbonne Nouvelle
Université de Paris IV Sorbonne
Université Descartes Paris 5
Université Curie, Paris 6
Université Diderot Paris 7
Université catholique de Paris
Université Paris VIII Vincennes à Saint Denis
Université Paris Ouest
Université Paris est Créteil Val de Marne   Paris XII
Université Paris XIII nord
Université Paris Est Marne la Vallée
Université de Cergy Pontoise
Université de Versailles Saint Quentin en Yvelines
Université d'Evry   Val d'Essonne
Université Paris sud   Paris XI
Université de Nimes
Université de Perpignan
Université de Limoges
Université de Lorraine
Université de Lorraine
Université de Lorraine
Université de Toulouse 1   Capitole
Université de Toulouse II   Le Mirail
Université Paul Sabatier
Institut Catholique de Toulouse
Université Champollion
Université d'Artois
Université de Lille 1
Université de Lille 2   Droit et Santé
Université Charles de Gaulle   Lille III
Université Catholique de Lille
Université du Littoral
Université de Valen ciennes
Université de Basse Normandie
Université du Havre
Université de Rouen
Université d'Angers
Université catholique de l'Ouest
Université du Maine
Université de Nantes
Université de Picardie   
Université de technologie de Compiègne
Université de La Rochelle
Université de Poitiers
Aix Marseille Université
Université d'Avignon
Université de Nice Sophia Antipolis
Université de Toulon
Université de Savoie
Université Joseph Fourier
Université Pierre Mendès France
Université Stendhal Grenoble III
Université Claude Bernard   Lyon I
Université Lumière   Lyon II
Université Jean Moulin   Lyon III
Université catholique de Lyon
Université Jean Monnet

Associations in Marseille | Marseille Conferences

Marseille has many associations which belong to various sectors and these associations aid in the growth of the state’s economy by providing a lot of funding programs. Some of the famous and reputed associations to be mentioned are,